Emerging targets in osteoarthritis therapy

Mary B Goldring[1,2] and Francis Berenbaum[3]

Osteoarthritis (OA) is a destructive joint disease in which the initiation may be attributed to direct injury and mechanical disruption of joint tissues, but the progressive changes are dependent on active cell-mediated processes that can be observed or inferred during the generally long time-course of the disease. Based on clinical observations and experimental studies, it is now recognized a that it is possible for individual patients to exhibit common sets of symptoms and structural abnormalities due to distinct pathophysiological pathways that act independently or in combination. Recent research that has focused on the underlying mechanisms involving biochemical cross talk among the cartilage, synovium, bone, and other joint tissues within a background of poorly characterized genetic factors will be addressed in this review.

Addresses
[1] Tissue Engineering, Regeneration and Repair Program, Hospital for Special Surgery, New York, NY, USA
[2] Department of Cell and Developmental Biology, Weill Cornell Medical College, New York, NY, USA
[3] Department of Rheumatology, AP-HP Saint-Antoine Hospital, 75012 Paris, France

Corresponding author: Goldring, Mary B (goldringm@hss.edu)

Introduction

Osteoarthritis (OA) is the most common joint disorder and is a leading cause of disability in the adult population. The disease manifestations in the joint are well characterized, including progressive loss of articular cartilage, cartilage calcification, osteophyte formation, subchondral bone remodeling, and mild to moderate inflammation of the synovial lining. Many therapeutic clinical trials have been conducted with designs based on subject selection related to the joint location or on whether the disease is primary or secondary to other types of arthritis [1–3]. Most trials, including those addressing targeted therapies, have evaluated patient-reported outcomes of function and pain at later stages of disease when there is radiographic evidence of damage, that is, joint space narrowing and osteophytes. However, symptoms and disease progression do not necessarily correspond in an individual patient and there is significant patient-to-patient variability in the time course of progression. Furthermore, the disease multifactorial process is impacted by aging, genetic predisposition, abnormal biomechanics, obesity, and trauma and influenced by co-morbidities such as cardiovascular disease, metabolic syndrome, and diabetes. Recognition that it may be possible to classify OA patients according to these diverse etiologies could optimize patient cohort selection for trial design [4–7].

Till date, no efficacious structure-modifying agent has been approved by any regulatory agency and available pain therapies are limited in efficacy and have associated toxicities [8]. Although there are promising candidates, there is a paucity of validated diagnostic and prognostic molecular biomarkers that could be used to evaluate efficacy in pre-symptomatic early-stage disease before irreversible joint damage [9,10,11•,12]. Imaging biomarkers are also under intensive study [13]. Given the complexity of OA, a single therapy will not be effective and therefore promising strategies should focus on how to address both symptoms and structural changes [14–17]. This review will focus on emerging strategies based on novel research findings that are undergoing validation and translation in pre-clinical models and have promise for development in proof-of-concept early phase trials and for informing the design of future definitive clinical trials.

Existing therapies and current research goals

Current guidelines consist of OA therapy in the following defined order: first, behavioral interventions; second, simple analgesic such as acetaminophen (paracetamol); third, nonsteroidal anti-inflammatory drugs, including COX-2 inhibitors [18]; fourth, intraarticular injection of hyaluronic acid or corticosteroid; and finally fifth, total joint replacement. Anti-pain drugs include opioids and centrally acting drugs such as duloxetine, which have adverse side effects. Since these current treatment options are lacking efficacy for the majority of patients, there is a great, unmet medical need that has been exacerbated by the recent closure of research programs by pharmaceutical companies wary of investing in identifying complex OA treatments and proving their efficacy in clinical trials [8].

Despite the identification of pro-inflammatory cytokines such as interleukin (IL) 1, which is used *in vitro* to mimic the catabolic responses that occur in OA, as potential targets in pre-clinical animal models, anti-cytokine

therapies that have been successful in other inflammatory and autoimmune diseases affecting joints have not proven to be effective against OA in clinical studies [19,20]. Preclinical studies indicate that MMP-13 is a crucial target for blocking cartilage erosion in OA [21] and that a number of other molecular targets should be amenable to therapy [22–24]. However, therapies that directly inhibit catabolic enzymes or signaling pathways, have inadequate efficacy or unacceptable side effects, even with increased specificity. Thus, many clinical programs addressing such products as OA therapies have been discontinued. This has fostered renewed efforts in the academic community to find novel strategies.

Emerging strategies for structure modification

Current research goals are directed toward understanding the different etiologies in terms of the common and distinct molecular mechanisms that would be amenable for targeted therapies. One classification scheme proposes a continuum of potential phenotypes [4] involving post-traumatic, metabolic, and aging-related (including post-menopausal), changes that are most prominent at young, middle, and advanced ages, respectively, as well as a genetic phenotype, in which different mutations produce susceptibility across an age-associated continuum [25]. Any of these OA phenotypes may be associated with abnormal biomechanics and malalignment as part of a whole-joint organ failure that frequently involves episodes of inflammation [26].

Laboratory studies using cell-based assays, animal models, and human OA joint tissues have identified a number of molecular pathways that are induced by mechanical, inflammatory, and oxidative stresses in the resident cells. In the cartilage, these stresses result in the release of the chondrocytes from growth arrest, loss of homeostasis, and activation of aberrant cellular signal transduction and gene expression [27]. Among the early events is the disruption of the pericellular matrix, associated with abnormal activation of cell surface receptors [28••,29]. The subsequent loss of surface lubrication is associated with proteoglycan loss and collagen erosion, while increased cartilage calcification and tidemark advancement or duplication are associated with vascular penetration from the subchondral bone. Since the damaged collagen network cannot be repaired to its original state, the challenge is to develop therapies that either prevent the destruction in the first place or promote repair to replicate the physiological and functional properties of the original cartilage.

Targeted therapies, however, have been elusive, since manipulation of any of the genes encoding potential targets by knockout or transgenic overexpression in mice can individually have profound effects on OA development [30,31]. For example, mice deficient in the crucial aggrecan-degrading and collagen-degrading genes, *Adamts5* and *Mmp13*, are protected against cartilage damage and other aspects of OA development. The mouse studies do not necessarily correspond with genome wide association studies (GWAS), which have identified genes that harbor OA susceptibility alleles, including *GDF5*, *SMAD3*, *DIO2*, *DIO3*, *RUNX2*, *PTHLH*, *CHST11*, *TP68*, *DOT1L*, *COL11A1*, *VEGF*, and *IGFBP3* [32–35]. Many of these, including GDF5, whose 143383C to T SNP has been validated thus far as the strongest OA-related variant and which is regulated by DNA methylation [36,37], are skeletal developmental genes that could be associated with cartilage calcification, osteophyte formation, and subchondral bone changes in OA [38]. On the other hand, proteomic profiling of OA synovial fluid indicates that a major proportion of the knee OA proteome contains acute phase response, coagulation, and complement proteins generated from the synovium [39]. Gene profiling data will probably enable subsetting of different OA populations into cohorts, but whether a single, one-drug-fits-all strategy will result is highly unlikely. Furthermore, profiling single patients to guide individualized OA therapy is a long-term future goal [12].

Inflammatory, mechanical, and oxidative stress

Inflammation can be observed at the macroscopic level as synovitis and synovial effusion during operative procedures such as arthroscopy or by MRI and is associated with more rapid progression to OA [40–43]. Recent studies, however, highlight a role for chronic low-grade inflammation, termed 'microinflammation', which is often associated with aging and can disrupt homeostasis in joint tissues and drive the degradative responses [44,45,46,47••]. This is an important consideration in OA joints, since mechanical stress may induce similar signaling responses in the absence of overt inflammation.

Oxidative stress, resulting from increased levels of reactive oxygen species (ROS) relative to antioxidants, may act together with inflammatory and/or mechanical stress to accentuate catabolic processes, depending upon the availability of signals and the state of the tissue damage. Mechanical injury, inflammatory cytokines, and matrix fragments, such as fibronectin fragments via integrins can induce ROS, and the age-related decline in the responses of chondrocytes to anabolic growth factors may be attributable to altered cell signaling mediated by increased oxidative stress [48,49]. NF-κB signaling is an integrating mechanism underlying most responses to inflammatory, mechanical, and oxidative stresses [27,50–52]. Components of NF-κB signaling are found prominently among the different gene signatures in experimental OA models [53].

Genomic and proteomic analyses of synovial fluids and joint tissues collected at the time of arthroscopic or joint

replacement surgery have indicated that there is a spectrum of cellular and molecular phenotypes from early through late-stage OA disease [39,54–56]. In patients with traumatic ACL or meniscal injury, but no radiographic evidence of OA, the synovium retrieved during arthroscopy is frequently inflamed and the inflammation scores are associated with increased pain and dysfunction, as well as unique cytokine and chemokine gene expression profiles [55]. High expression of genes encoding cytokines, chemokines, proteinases, and NF-κB signaling molecules may also be observed in meniscus samples from patients with both meniscal and ACL tears [57]. Gene signatures associated with the immune response, inflammation, cell cycle, and cellular proliferation are increased with aging in the damaged meniscus, whereas genes associated with cartilage and skeletal development and extracellular matrix synthesis are repressed [58].

Cartilage is an avascular tissue, and as the normal environment for chondrocytes, hypoxia is important for the maintenance of homeostasis via hypoxia inducible factor (HIF)-1α. During oxidative stress, NF-κB signaling is required for the induction of HIF-2α, which regulates both endochondral ossification and OA-related cartilage destruction, in part, by directly targeting HREs within the MMP13 COL10A1, and VEGFA promoters [52,59] and by inducing proteinases and inflammatory genes in chondrocytes [60]. The down-regulation of HIF-1α and 2α target genes and up-regulation of HIF-3α appear to be part of the mechanism by which overexpression of PRG4, the gene encoding lubricin, prevents the induction of catabolic and hypertrophy-related responses and protects against aging-related or post-traumatic OA development in mice [61••]. Another novel pathway is the Zinc-ZIP8-MTF1 axis [62••]. ZIP8, a Zn^{2+} transporter, which is highly upregulated by IL-1β, induces MMP3, 9, 12, and 13 and ADAMTS5 gene expression via MTF1 (metal regulatory transcription factor-1), which is induced by hypoxia and oxidative stress [62••].

The requirement of canonical NF-κB signaling for the induction of HIF2α [59] and other inflammation-inducible transcription factors such as Elf3 [63] and the cooperation HIF2α with C/EBPβ and Runx2 [64] suggest the importance of an integrated network converging on transcriptional regulation of MMP13 and other catabolic and inflammatory genes. In contrast, the non-canonical NF-κB signaling kinase, IKKα/CHUK, promotes the aberrant expression of genes involved in endochondral ossification, including Runx2, COL10A1, and VEGF, but not MMP13. The increased MMP-13 activity and collagen remodeling can be attributed to the increased gene expression of MMP-10, an activator of MMPs [65••].

Adaptive and innate immunity
Evidence for a role of adaptive immunity in OA is restricted to the initial interactions of T cells that can be activated in response to the damage associated molecular patterns (DAMPs), also known as alarmins, which can be released from degraded cartilage and other tissues [66]. However, during the chronic phase, the innate immune system plays an important role in the initiation and perpetuation of the low-grade inflammation in OA [40,41,67–69] through cellular activation by DAMPs, including high mobility group box-1 (HMGB1), S100A8 (MRP8, calgranulin A) and S100A9 (MRP14, calgranulin B), serum amyloid A (SAA), collagen and proteoglycan constituents, and calcium pyrophosphate or hydroxyapatite crystals. These extracellular ligands interact with pattern recognition receptors (PRRs) such as toll-like receptors (TLR)-2 and TLR-4 and the receptor for advanced glycation end-products (RAGE) to induce cellular inflammatory responses via NF-κB to drive synovitis and cartilage destruction [45,70]. DAMPs serve homeostatic functions eliciting sterile wound healing and tissue repair, but in OA it is not clearly defined where, when, and how the ligands are generated and whether these are initiating or amplifying events. Nevertheless, TLR4, which has been well studied in the context of LPS activation and for which many inhibitory compounds exist, has been proposed as a direct and specific target for candidate OA disease-modifying agents [71]. However, deficiency of TLR-1, 2, 4, or 6 or their shared signaling molecule MyD88 has no effect on OA development in mice with partial meniscectomy [72].

Complement proteins are additional candidates detected in synovial fluids of OA patients by proteomic analysis [39,54,73,74]. DAMPs, including COMP, fibromodulin, the collagen XI NC4 domain, and the C-type lectin of the aggrecan G3 domain, can activate complement pathways [75,76]. The classical, mannose-binding lectin, and alternative complement pathways all converge on C3 to activate the membrane attack complex (MAC) formed from the complement effector C5b-C9. Knockout of the C5 and C6 components or pharmacological treatment with CR2-fH attenuates joint damage in the medial meniscectomy mouse model, whereas knocking out the naturally occurring complement inhibitor CD49 or deficiency of carboxypeptidase increases degenerative changes [77,78].

Autophagy, cell survival, and bioenergetics
Chondrocytes are post-mitotic cartilage cells, and due to their virtually absent proliferative activity in adult articular cartilage, they use autophagy as a very efficient housekeeping program to maintain cellular function and homeostasis by removing damaged or malfunctioning cellular structures, eliminating exogenous cellular aggressors, and providing alternative sources of energy during ER stress, hypoxia, starvation, and other adverse events [79,80]. Three autophagy-related pathways have been described in mammalian cells based on cellular localization and markers, including Atg5, and Atg7 for

microautophagy (MA), Hsc-70 and LAMP-2A for chaperone-mediated autophagy (CMA), and Hsc-70, Vps4 and Tsg101 for endosomal microautophagy (eCI) [79]. In all cases, LC3 is recruited to the nascent autophagosome and cleaved upon fusion between the autophagosome and the lysosome or endosome; its cleavage, termed LC3 flux, is used to assess the efficiency of fusion [81].

The loss of autophagy in articular cartilage under mechanical or inflammatory stress is linked to aging-related cell death and increasing OA severity [82,83]. LC3 and beclin 1 are upregulated in chondrocytes in OA cartilage and in response to inflammatory and nutritional stress in a manner dependent upon ATG5 [84]. Rapamycin, an inhibitor of mTOR that can increase the lifespan of middle-aged mice, reduces the severity of experimental murine OA by inhibiting ribosomal protein S6 phosphorylation, a target of mTOR signaling. Rapamycin-induced activation of LC3 increases ULK1, beclin 1, and LC3, promotes chondrocyte survival, decreases synovitis and ADAMTS5 and IL-1β, and prevents glycosaminoglycan loss [85,86]. PPARγ, which has roles in obesity and inflammation, also maintains homeostasis, in part by regulating mTOR [87].

Compared to autophagy, which is lysosome-mediated or endosome-mediated, the unfolded protein response (UPR) is a non-lysosomal pathway for ubiquitin/proteasome degradation of unfolded proteins eliminated from the endoplasmic reticulum (ER) [47••]. The UPR is important for the normal differentiation program in chondrocytes proceeding to hypertrophy and apoptosis during growth plate development [88–90]. Inflammatory, mechanical, and oxidative stress can induce ER stress and the UPR in cartilage via C/EBP homologous protein (CHOP) and X-box protein 1 (XBP1) [47••], both of which potentiate IL-1β-induced oxidative stress and pro-catabolic responses [91]; however, XBP1 can promote chondrocyte survival under certain conditions [92].

Also related to autophagy are the classic cell survival signals, phosphatidylinositol-3 kinase (PI3K) and its downstream target serine-threonine kinase (AKT) [93–95]. A key negative regulator of the PI3K/AKT pathway is the tumor suppressor gene, phosphatase and tensin homolog deleted on chromosome ten (PTEN), which is elevated PTEN in OA chondrocytes [96].

How autophagy and ER stress could be targeted for alleviating cartilage damage or pain in OA is not clear. Global *Chop* knockout partially protects against chondrocyte apoptosis and cartilage degradation in a mouse OA model, but without detectable modification of ER stress [97]. Cartilage-specific knockout of mTOR also protects mice from OA by upregulating autophagy [98]. However, since rapamycin, an mTOR inhibitor, has immunosuppressive side effects, nutrient supplementation with spermidine, polyamines, or ω-6 polyunsaturated fatty acids, which increase lifespan in lower organisms or treatments with activators of the ubiquitin-proteosome system could be considered, although more work would be required to prove safety, specificity, and efficacy [80]. Glucosamine can also activate autophagy *in vitro* and *in vivo* via a mechanism dependent on the Akt//Fox03/mTOR pathway [99].

Articular chondrocytes rely on long diffusion pathways to obtain oxygen and derive ATP for their bioenergy needs from high basal glycolysis. Mitochondrial oxidative phosphorylation (OXPHOS) accounts for up to one-fourth of the total steady-state ATP production within articular cartilage. The impairment of chondrocyte mitochondrial function has emerged as a mechanism involved in impaired autophagy and deregulated bioenergetics in OA [100]. The oxidative stress damages the mitochondrial respiratory chain protein complexes resulting in decreased chondrocyte mitochondrial ATP generation, loss of the chondrocyte energy reserve, impaired matrix synthetic function, and decreased chondrocyte viability [100]. Certain mitochondrial haplotypes predispose to OA [101] and depletion of the antioxidant SOD2 promotes mitochondrial dysfunction and increases ROS in chondrocytes [102]. Furthermore, mitochondrial dysfunction can amplify the stress responses through increased nitric oxide generation, ROS production and NF-κB activation [102–104].

The serine/threonine kinase, AMPK, and the nicotinamide adenine dinucleotide (NAD+)-dependent protein deacetylase, SIRT1, act together to balance energy metabolism and coordinate several housekeeping activities, including autophagy, in the resistance to cell stress and inflammation by normalizing mitochondrial function [105]. Upon its activation by AMPK through increased intracellular NAD+, SIRT1 deacetylates liver protein kinase B1 (LKB1, which in turn activates AMPK in a positive feedback loop [106]. They also limit NF-κB induction of catabolic and inflammatory responses by deacetylating the p65 NF-κB subunit and priming it for proteasomal degradation, promoting autophagy through repair of damaged mitochondria [80,106–109]. Studies in OA and aging models suggest protective roles for SIRT1 and AMPK in cartilage [107–114]. Pharmacologic SIRT1 activation with resveratrol exerts chondroprotective effects, suggesting a potential therapeutic strategy through normalizing bioenergetics [15].

Angiogenesis and cartilage/subchondral bone interactions

Angiogenesis and sensory nerve growth are closely integrated processes that are potentially linked to the elevated crosstalk between the bone and cartilage in OA. Articular cartilage is normally avascular and aneural and is separated from the subchondral bone by a zone of

calcified cartilage, with the tidemark as the histologically defined interface between the articular and calcified cartilage. Microcracks produced by mechanical stress and exacerbation of naturally occurring pores in the subchondral bone plate provide conduits for vascular invasion into the calcified cartilage and enable cross-talk through diffusion of small molecules [115,116]. TGF-β-mediated angiogenesis, potentially among the earliest events driving OA [117], is followed by vascular invasion into the osteochondral junction [118,119]. Examination of OA mouse models by microCT shows early and temporal subchondral plate porosity and increased perforation with enhanced biochemical and mechanical interactions among the subchondral trabeculae, bone marrow cells, and articular cartilage. The advancement of the calcified cartilage, associated with tidemark duplication, into the deep zones of the articular cartilage leads to local cartilage thinning, thereby compromising the mechanical function of the osteochondral unit [120].

The regions of vascular invasion are associated with localized bone marrow replacement by fibrovascular tissue containing cells that express VEGF, accompanied by increased osteoclast activity, infiltration of inflammatory cells into the marrow spaces, and increased endothelial cell proliferation and vascular density [121]. The invasive vascular elements in calcified cartilage and synovium may serve as conduits for nerve fibers and stimuli for nerve growth factor (NGF) [122]. VEGF is expressed by chondrocytes in proximity to the angiogenesis, suggesting that it is involved in recruiting vascular elements. Gene expression profiling identified STC1, a gene encoding stanniocalcin-1, which regulates angiogenic sprouting via the VEGF/VEGF receptor 2 pathway, as the most highly up-regulated gene in inflamed synovial membrane compared to non-inflamed synovium from the same OA patients [123]. A recent study shows that VEGF blockade with bevacizumab inhibits post-traumatic OA in a rabbit model with pain relief possibly associated with prevention of both synovitis and angiogenesis [124].

Cartilage anabolism and tissue engineering strategies

Since members of the TGF-β/BMP superfamily have roles in chondrogenesis and articular cartilage maintenance, they have been used as additive factors in tissue engineering strategies. However, TGF-β signaling can play both protective and deleterious roles in OA, explained in part by the alteration of signaling pathways in aging chondrocytes through decreased ALK5, the canonical receptor that activates Smad2/3 to inhibit chondrocyte hypertrophy, and increased ALK1, which signals through Smad1/5/8 to induce MMP-13 and cartilage catabolism [125] and NGF [126]. Disruption of the pericellular matrix by the TGF-β-induced serine proteinase, HTRA1, may be one of the earliest events in OA chondrocyte activation [28••]. These aberrant chondrocyte

responses may account for the off-target effects of TGF-β injections in joints that result in osteophyte formation and synovial fibrosis.

Recent studies have also identified aberrant TGF-β signaling in bone as a key pathway in OA [127]. In the ACL transection model of OA, high doses of a TGF-β inhibitor administered systemically promoted cartilage proteoglycan loss, whereas lower doses prevented the migration and/or localization of MSCs, osteoprogenitors, and osteoblasts in the subchondral bone of operated limbs and attenuated neovascularization and cartilage loss. Transgenic expression of active TGF-β in osteoblasts induced the formation of nestin-positive MSCs in clusters, whereas knockout of *Tgfbr2* in nestin-positive MSCs prevented MSC migration to the subchondral bone and normalized bone parameters, cartilage homeostasis, and limb function. Furthermore, implantation of a TGF-β-specific antibody in the subchondral bone attenuated the OA changes in both the cartilage and bone, suggesting that bone-targeted therapies may be useful in some forms of the disease [117].

The FGFs are generally considered homeostatic factors in joint tissues [128], but FGF-2, for example, can be chondroprotective through FGFR3 or promote cartilage destruction via FGFR1 [129]. Of the four receptors, FGFR1 and 3 are the most abundant, and the ratio of FGFR3 to FGFR1 is reduced in OA cartilage. FGF-18 via FGFR3 also protects against loading-induced damage in cartilage explants *ex vivo* [130] and intraarticular administration of FGF18 protects against cartilage damage in a rat model of injury-induced arthritis [131]. Thus, there is considerable interest in the potential of anabolic factors such as FGF-18 for enhancing cartilage regeneration with tissue engineering approaches [132]. However a recent proof-of-concept trial with human recombinant FGF-18, sprifermin, showed statistically significant dose-dependent improvement in pre-specified secondary structural end points by MRI, radiographic joint space narrowing, and WOMAC pain scores [133].

Targeting the Wnt/β-catenin pathway, which plays a role in both cartilage and bone development and pathology [134,135], has been investigated in OA, but with contrasting results. The Wnt antagonists, dickkopf-related protein-1 (DKK-1) and secreted frizzled-related protein 1 (sFRP1), along with the BMP antagonist Gremlin1, can prevent these adverse effects on articular cartilage homeostasis by decreasing hypertrophic differentiation [136,137•] and expression of proteinases [138]. GWAS have identified unique polymorphisms associated with hip OA in the FRZB gene encoding sFRP1 [139], which may have a protective role in OA by inhibiting MMP induction in chondrocytes [140]. However, differential effects of DKK-1 may be observed on cartilage and bone depending on dosage and mode of delivery and a recent

study suggests that the inhibition of cartilage degradation by DKK-1 is related to its capacity to inhibit VEGF production by osteocytes and osteoblasts [141].

Another Wnt antagonist, sclerostin (SOST) identified originally as an osteocyte-specific, is expressed in cartilage and found at low levels in osteochondral tissues, plasma, and synovial fluid in OA patients and/or animal models [142,143], SOST inhibitors that increase bone formation have been developed [144], but neither SOST deficiency in mice nor pharmacological inhibition in a rat meniscal tear model appears to impact on cartilage remodeling [145].

These conflicting findings may be related to the availability of Wnt ligands in different tissues and their use of distinct, canonical versus non-canonical, pathways over the course of differentiation and during pathology [134]. Consistent with this notion are findings from gene expression profiling comparing articular chondrocytes with prominent expression of BMP and Wnt signaling antagonists and osteophytic chondrocytes expressing genes involved in endochondral ossification [146]. Canonical Wnt signaling induced by Wnt3a or WISP1 promotes the switch of TGF-β signaling toward ALK1 and Smad 1/5/8 [137•] and mechanical load-mediated suppression of SOST requires TGF-β [147]. Although lithium chloride stimulates β-catenin signaling via inhibition of GSK-3, it inhibits catabolic events in surgically induced OA in mice via NF-κB, p38, and Stat3 signaling [148].

The predominant research strategy aimed at engineering functional cartilage with the identical properties of the native tissue has been to increase the accumulation of a cartilaginous matrix by exposing cells to anabolic agents such as those discussed above, either through exogenous addition of recombinant proteins or genetic manipulation of the cells to overexpress them. This work has led to development of scaffold materials, identification of viable cell sources and culture conditions, including growth

Table 1

Emerging targets in structure modification and neuroinflammation-driven chronic pain

Biological process	Targets (downstream effectors)	Potential therapeutics
Cartilage degradation	DDR2 activated by TGFβ-induced HTRA1 serine proteinase [28••]	Tyrosine kinase inhibitors
	ADAM17 (via activating TNFα and EGFR ligands, e.g., TGFα [157–159])	Serine proteinase inhibitors
	Cathepsin K [160]	MMP inhibitors [161]
		Neutriceuticals, for example, green tea polyphenol [162]
		CatK inhibitors
Mechanical, inflammatory, and oxidative stress	Canonical NF-κB signaling [163]	Curcumin, resveratrol, IKKβ inhibitor (SAR113945); proteasome inhibitor (bortezomib) [164]
	JAK/STAT signaling [7]	Tofacitinib [165]; SOCS [166,167]
	Reactive oxygen species	Anti-oxidants, iNOS inhibitors; mitochondrial ROS scavengers [168]
	HIF-2α (proteinases and hypertrophy markers) [52,60]	Antioxidants
	Zinc-ZIP8-MTF1 axis (MMPs, ADAMTS5) [62••]	
Innate immunity	TLRs [71,72]	6-shogaol; boswellic acid; kampferol; oleocanthal; quercetin
	Complement [77,78]	CR2-fH
Chondrocyte hypertrophy	Hedgehog signaling [169,170]	Small molecule inhibitors of Gli, Smo, etc.
	IKKα (MMP10) [65••]	
	ADAM10 (Notch signaling via RBPjk) [171–173]	
Angiogenesis and synovitis	[a]VEGF [124]	Bevacizumab [124]
Subchondral bone	WNT/β-catenin [174]	Sclerostin, DKK-1
	Adenosine receptors [175]	A2AR antagonists
Pain	[a]Monocyte chemoattractant protein (MCP1)/CCR2 chemokine receptor [150••]	CCR2 receptor antagonist
	[a]Peripheral calcitonin gene-related peptide receptor (CGRP)	CGRP 8-37 receptor antagonist [151]
	[a]Transient receptor potential vanilloid ion channels (e.g., TRPV4)	TRPV4 agonist (GSK1016790A) [152••]
	[a]Adenosine and purinergic receptors (via TRPV channels) [176,177]	A3AR agonists; P2X and P2Y antagonists

[a]Both structure modification and pain relief have been demonstrated in animal models.

factor delivery and mechanical stimulation, as well as approaches for delivering cells alone or in a scaffold to the injury site. However, we are far from achieving a construct with the mechanical stability and lubricating properties of native cartilage. Successful cartilage tissue engineering strategies must also include retention of key matrix components within the construct over an extended lifespan and under inflammatory conditions and integration with the host tissue. Among the cell sources are mesenchymal stem cells (MSCs), which can be obtained from autologous adipose tissue, bone marrow, or muscle and expanded *ex vivo* in conditions that promote chondrogenesis. Although articular chondrocytes have no intrinsic repair capacity, the potential of a small population of cartilage-derived stem or progenitor cells to be stimulated *in situ* is the subject of current investigations [149••].

Prospects for the future
Application of our knowledge regarding the anti-inflammatory, anti-catabolic, and pro-anabolic factors to developing new structure modifying therapies is a promising outcome of the future. Also, a number of established OA susceptibility loci have been determined in large population studies, but functional follow-up is needed and their use for establishing cohorts for clinical trials is a future goal. Although clinical trials are ongoing to assess agents that address some of these targets, OA in humans develops slowly with time and may not be symptomatic until significant joint damage occurs. Thus, it has been extremely difficult to develop disease-modifying drugs and prove their effectiveness in clinical trials due to the lack of biomarkers and sensitive techniques for identifying

and assessing patients with early changes. In the meantime, research efforts are evaluating more specific inhibitors that target OA disease-specific mechanisms in preclinical animal models that reflect different OA phenotypes [30,31]. Some of the emerging targets are summarized in Table 1.

Emerging targets in neuroinflammation-driven chronic pain include many factors involved in structure modification in OA. Studies in mouse OA models show central roles of nociception during inflammation, neuropathy, and mechanosensitivity and have identified several promising targets that affect physical function and pain sensitivity [150••,151,152••], as indicated in Table 1. Emerging mediators and molecular therapies that ameliorate OA and in some cases can even promote regeneration in animal models are summarized in Table 2.

As in other complex diseases, analysis of the structure and dynamics of molecular networks could give system-level understanding of potential targets of therapy and improve the efficiency of drug discovery [153]. Our recent ability to profile unique patterns of epigenetic changes offers novel strategies for distinguishing diverse chondrocyte phenotypes that relate to chondrogenic programming, articular cartilage homeostasis, and OA disease progression, and for identifying novel biomarkers of early OA, such as circulating long non-coding RNAs and miRNAs [154•,155]. Correlating DNA methylation, chromatin marks, and miRNA signatures in human OA disease with those found in well-defined OA animal models could

Table 2

Emerging mediators and molecular therapies that ameliorate OA and in some cases can even promote regeneration

Biological process	Mediators	Potential therapeutics[a]
Autophagy and cell survival	mTOR [85,98]; AKT/Fox03/mTOR [99]; PPARγ [87,178,179] CXCR2 [180•]	Rapamycin, polyamines, ω-6 polyunsaturated fatty acids; glucosamine Chemokine antagonists or blocking antibodies
Chondrogenesis and inhibition of endochondral ossification	Runx1 PTH receptor EGFR signaling	TD-198946 [181]; Kartogenin [182,183] Recombinant human PTH (1-34) (teriparatide) [184] Mitogen-inducible gene 6 (MIG6) [185]
Calcification and crystals	NPP1 [186]; transglutaminase, inorganic pyrophosphate, TLRs, NLRP3	Phosphocitrates, TLR and NLRP3 inhibition
Subchondral bone	WNT/β-catenin BMPs BMP-7 TGF-β [117]	Wnt antagonists (DKK1, SOST) BMP antagonists (Gremlin, follistatin) [136,137•,138,141] Recombinant BMP-7 (Eptotermin) [187] TGF-β-specific antibody
Cartilage anabolism	IGF-1 FGF-18 PRG4 [61••] NFATc2/c2 [192] Calcitonin [193]	Humanized IGF-1-heparin-binding domain fusion protein [188] Sprifermin [133] Oral or intraarticular calcitonin [189–191]
Circadian clock	Bmal1 [194•]	REV-ERB agonists [195]

[a]Both pre-clinical and clinical studies referred to without comment on efficacy.

allow us to define the different regulatory requirements for stress-related phenotypes of OA chondrocytes [156]. However, although therapies that target DNA or histone methylation or miRNAs have been considered for cancer, their use in a non-life-threatening disease such as OA will require better understanding of gene and target cell specificities to avoid cytotoxicity and off-target effects. The academic community remains hopeful that rational molecular therapies may be on the horizon if their findings in pre-clinical models can be translated to proof-of-principle clinical trials designed to provide clear outcomes.

Conflict of interest statement

Dr. Goldring has received research support in the past three years from AbbVie, Biogen-IDEC, and Merck-Serono and consulting fees from FIDIA Farmaceutici and Endocyte; Dr Berenbaum has received research support in the past three years from Servier, TRB Chemedica and Pierre Fabre, and consulting fees from AbbVie, Pfizer, Akros, Janssen and IBSA.

Acknowledgements

References and recommended reading

Papers of particular interest, published within the period of review, have been highlighted as:

- • of special interest
- •• of outstanding interest

1. Kloppenburg M: **Hand osteoarthritis-nonpharmacological and pharmacological treatments**. *Nat Rev Rheumatol* 2014, **10**:242-251.

2. Stiebel M, Miller LE, Block JE: **Post-traumatic knee osteoarthritis in the young patient: therapeutic dilemmas and emerging technologies**. *Open Access J Sports Med* 2014, **5**:73-79.

3. Detert J, Klaus P, Listing J, Hohne-Zimmer V, Braun T, Wassenberg S, Rau R, Buttgereit F, Burmester GR: **Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands (OA TREAT): study protocol for a randomized controlled trial**. *Trials* 2014, **15**:412.

4. Bijlsma JW, Berenbaum F, Lafeber FP: **Osteoarthritis: an update with relevance for clinical practice**. *Lancet* 2011, **377**:2115-2126.

5. Blanco FJ, Ruiz-Romero C: **Osteoarthritis: metabolomic characterization of metabolic phenotypes in OA**. *Nat Rev Rheumatol* 2012, **8**:130-132.

6. Conaghan PG: **Osteoarthritis in 2012: parallel evolution of OA phenotypes and therapies**. *Nat Rev Rheumatol* 2013, **9**:68-70.

7. Henrotin Y: **Does signaling pathway inhibition hold therapeutic promise for osteoarthritis?** *Joint Bone Spine* 2014, **81**:281-283.

8. Matthews GL, Hunter DJ: **Emerging drugs for osteoarthritis**. *Expert Opin Emerg Drugs* 2011, **16**:479-491.

9. Lafeber FP, van Spil WE: **Osteoarthritis year 2013 in review: biomarkers; reflecting before moving forward, one step at a time**. *Osteoarthritis Cartilage* 2013, **21**:1452-1464.

10. Lotz M, Martel-Pelletier J, Christiansen C, Brandi ML, Bruyere O, Chapurlat R, Collette J, Cooper C, Giacovelli G, Kanis JA *et al.*: **Value of biomarkers in osteoarthritis: current status and perspectives**. *Ann Rheum Dis* 2013, **72**:1756-1763.

11. Hsueh MF, Onnerfjord P, Kraus VB: **Biomarkers and proteomic**
   •   **analysis of osteoarthritis**. *Matrix Biol* 2014, **39**:56-66.
   This recent review catalogues current status on available and emerging biomarkers in relation to proteomic analyses that have been done in serum, urine, and synovial fluid from health non-OA subjects compared to OA patients.

12. Tonge DP, Pearson MJ, Jones SW: **The hallmarks of osteoarthritis and the potential to develop personalised disease-modifying pharmacological therapeutics**. *Osteoarthritis Cartilage* 2014, **22**:609-621.

13. Hunter DJ, Eckstein F, Kraus VB, Losina E, Sandell L, Guermazi A: **Imaging biomarker validation and qualification report: sixth OARSI Workshop on Imaging in Osteoarthritis combined with third OA Biomarkers Workshop**. *Osteoarthritis Cartilage* 2013, **21**:939-942.

14. Mobasheri A: **The future of osteoarthritis therapeutics: emerging biological therapy**. *Curr Rheumatol Rep* 2013, **15**:385.

15. Mobasheri A: **The future of osteoarthritis therapeutics: targeted pharmacological therapy**. *Curr Rheumatol Rep* 2013, **15**:364.

16. Pulsatelli L, Addimanda O, Brusi V, Pavloska B, Meliconi R: **New findings in osteoarthritis pathogenesis: therapeutic implications**. *Ther Adv Chronic Dis* 2013, **4**:23-43.

17. Thakur M, Dickenson AH, Baron R: **Osteoarthritis pain: nociceptive or neuropathic?** *Nat Rev Rheumatol* 2014, **10**:374-380.

18. Crofford LJ: **Use of NSAIDs in treating patients with arthritis**. *Arthritis Res Ther* 2013, **15(Suppl 3)**:S2.

19. Dinarello CA, Simon A, van der Meer JW: **Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases**. *Nat Rev Drug Discov* 2012, **11**:633-652.

20. Chevalier X, Eymard F, Richette P: **Biologic agents in osteoarthritis: hopes and disappointments**. *Nat Rev Rheumatol* 2013, **9**:400-410.

21. Wang M, Sampson ER, Jin H, Li J, Ke QH, Im HJ, Chen D: **MMP13 is a critical target gene during the progression of osteoarthritis**. *Arthritis Res Ther* 2013, **15**:R5.

22. Fosang AJ, Beier F: **Emerging frontiers in cartilage and chondrocyte biology**. *Best Pract Res Clin Rheumatol* 2011, **25**:751-766.

23. Wisniewski HG, Colon E, Liublinska V, Karia RJ, Stabler TV, Attur M, Abramson SB, Band PA, Kraus VB: **TSG-6 activity as a novel biomarker of progression in knee osteoarthritis**. *Osteoarthritis Cartilage* 2014, **22**:235-241.

24. Attur M, Krasnokutsky-Samuels S, Samuels J, Abramson SB: **Prognostic biomarkers in osteoarthritis**. *Curr Opin Rheumatol* 2013, **25**:136-144.

25. Sandell LJ: **Etiology of osteoarthritis: genetics and synovial joint development**. *Nat Rev Rheumatol* 2012, **8**:77-89.

26. Loeser RF, Goldring SR, Scanzello CR, Goldring MB: **Osteoarthritis: a disease of the joint as an organ**. *Arthritis Rheum* 2012, **64**:1697-1707.

27. Goldring MB, Otero M, Plumb DA, Dragomir C, Favero M, El Hachem K, Hashimoto K, Roach HI, Olivotto E, Borzi RM *et al.*: **Roles of inflammatory and anabolic cytokines in cartilage metabolism: signals and multiple effectors converge upon MMP-13 regulation in osteoarthritis**. *Eur Cell Mater* 2011, **21**:202-220.

28. Xu L, Golshirazian I, Asbury BJ, Li Y: **Induction of high**
   •• **temperature requirement A1, a serine protease, by TGF-β1 in articular chondrocytes of mouse models of OA**. *Histol Histopathol* 2014, **29**:609-618.
   The mechanism addressed in this paper suggests that the induction of serine protease, HTRA1, and its activity on the pericellular matrix is one of the earliest events in OA that could be targeted for therapy.

29. Pap T, Bertrand J: **Syndecans in cartilage breakdown and synovial inflammation**. *Nat Rev Rheumatol* 2013, **9**:43-55.

30. Little CB, Hunter DJ: **Post-traumatic osteoarthritis: from mouse models to clinical trials**. *Nat Rev Rheumatol* 2013, **9**:485-497.

31. Vincent TL, Williams RO, Maciewicz R, Silman A, Garside P: **Mapping pathogenesis of arthritis through small animal models**. *Rheumatology* 2012, **51**:1931-1941.

32. Reynard LN, Loughlin J: **Insights from human genetic studies into the pathways involved in osteoarthritis**. *Nat Rev Rheumatol* 2013, **9**:573-583.

33. Rodriguez-Fontenla C, Calaza M, Evangelou E, Valdes AM, Arden N, Blanco FJ, Carr A, Chapman K, Deloukas P, Doherty M *et al.*: **Assessment of osteoarthritis candidate genes in a meta-analysis of nine genome-wide association studies**. *Arthritis Rheumatol* 2014, **66**:940-949.

34. Evans DS, Cailotto F, Parimi N, Valdes AM, Castano-Betancourt MC, Liu Y, Kaplan RC, Bidlingmaier M, Vasan RS, Teumer A *et al.*: **Genome-wide association and functional studies identify a role for IGFBP3 in hip osteoarthritis**. *Ann Rheum Dis* 2014 http://dx.doi.org/10.1136/annrheumdis-2013-204599. [Epub ahead of print].

35. Gonzalez A: **Osteoarthritis year 2013 in review: genetics and genomics**. *Osteoarthritis Cartilage* 2013, **21**:1443-1451.

36. Reynard LN, Bui C, Syddall CM, Loughlin J: **CpG methylation regulates allelic expression of GDF5 by modulating binding of SP1 and SP3 repressor proteins to the osteoarthritis susceptibility SNP rs143383**. *Hum Genet* 2014, **133**:1059-1073.

37. Syddall CM, Reynard LN, Young DA, Loughlin J: **The identification of trans-acting factors that regulate the expression of GDF5 via the osteoarthritis susceptibility SNP rs143383**. *PLoS Genet* 2013, **9**:e1003557.

38. van der Kraan PM, van den Berg WB: **Chondrocyte hypertrophy and osteoarthritis: role in initiation and progression of cartilage degeneration?** *Osteoarthritis Cartilage* 2012, **20**:223-232.

39. Ritter SY, Subbaiah R, Bebek G, Crish J, Scanzello CR, Krastins B, Sarracino D, Lopez MF, Crow MK, Aigner T *et al.*: **Proteomic analysis of synovial fluid from the osteoarthritic knee: comparison with transcriptome analyses of joint tissues**. *Arthritis Rheum* 2013, **65**:981-992.

40. de Lange-Brokaar BJ, Ioan-Facsinay A, van Osch GJ, Zuurmond AM, Schoones J, Toes RE, Huizinga TW, Kloppenburg M: **Synovial inflammation, immune cells and their cytokines in osteoarthritis: a review**. *Osteoarthritis Cartilage* 2012, **20**:1484-1499.

41. Scanzello CR, Goldring SR: **The role of synovitis in osteoarthritis pathogenesis**. *Bone* 2012, **51**:249-257.

42. Scanzello CR, Albert AS, Dicarlo E, Rajan KB, Kanda V, Asomugha EU, Swaim BH, Katz JN, Goldring SR, Richmond JC *et al.*: **The influence of synovial inflammation and hyperplasia on symptomatic outcomes up to 2 years post-operatively in patients undergoing partial meniscectomy**. *Osteoarthritis Cartilage* 2013, **21**:1392-1399.

43. Guermazi A, Hayashi D, Roemer FW, Zhu Y, Niu J, Crema MD, Javaid MK, Marra MD, Lynch JA, El-Khoury GY *et al.*: **Synovitis in knee osteoarthritis assessed by contrast-enhanced magnetic resonance imaging (MRI) is associated with radiographic tibiofemoral osteoarthritis and MRI-detected widespread cartilage damage: the MOST study**. *J Rheumatol* 2014, **41**:501-508.

44. Tchkonia T, Zhu Y, van Deursen J, Campisi J, Kirkland JL: **Cellular senescence and the senescent secretory phenotype: therapeutic opportunities**. *J Clin Invest* 2013, **123**:966-972.

45. Liu-Bryan R, Terkeltaub R: **The growing array of innate inflammatory ignition switches in osteoarthritis**. *Arthritis Rheum* 2012, **64**:2055-2058.

46. Houard X, Goldring MB, Berenbaum F: **Homeostatic mechanisms in articular cartilage and role of inflammation in osteoarthritis**. *Curr Rheumatol Rep* 2013, **15**:375.

47. Liu-Bryan R, Terkeltaub R: **Emerging regulators of the
•• inflammatory process in osteoarthritis**. *Nat Rev Rheumatol* 2015, **11**:35-44.
This recent article reviews recent findings on mechanisms of innate immunity and microinflammation in OA.

48. Loeser RF: **Integrins and chondrocyte–matrix interactions in articular cartilage**. *Matrix Biol* 2014, **39**:11-16.

49. Loeser RF, Gandhi U, Long DL, Yin W, Chubinskaya S: **Aging and oxidative stress reduce the response of human articular chondrocytes to insulin-like growth factor 1 and osteogenic protein 1**. *Arthritis Rheumatol* 2014, **66**:2201-2209.

50. Marcu KB, Otero M, Olivotto E, Borzi RM, Goldring MB: **NF-κB signaling: multiple angles to target OA**. *Curr Drug Targets* 2010, **11**:599-613.

51. Nam J, Aguda BD, Rath B, Agarwal S: **Biomechanical thresholds regulate inflammation through the NF-κB pathway: experiments and modeling**. *PLoS One* 2009, **4**:e5262.

52. Saito T, Fukai A, Mabuchi A, Ikeda T, Yano F, Ohba S, Nishida N, Akune T, Yoshimura N, Nakagawa T *et al.*: **Transcriptional regulation of endochondral ossification by HIF-2α during skeletal growth and osteoarthritis development**. *Nat Med* 2010, **16**:678-686.

53. Poulet B, Ulici V, Stone TC, Pead M, Gburcik V, Constantinou E, Palmer DB, Beier F, Timmons JA, Pitsillides AA: **Time-series transcriptional profiling yields new perspectives on susceptibility to murine osteoarthritis**. *Arthritis Rheum* 2012, **64**:3256-3266.

54. Gobezie R, Kho A, Krastins B, Sarracino DA, Thornhill TS, Chase M, Millett PJ, Lee DM: **High abundance synovial fluid proteome: distinct profiles in health and osteoarthritis**. *Arthritis Res Ther* 2007, **9**:R36.

55. Scanzello CR, McKeon B, Swaim BH, DiCarlo E, Asomugha EU, Kanda V, Nair A, Lee DM, Richmond JC, Katz JN *et al.*: **Synovial inflammation in patients undergoing arthroscopic meniscectomy: molecular characterization and relationship to symptoms**. *Arthritis Rheum* 2011, **63**:391-400.

56. Mateos J, Lourido L, Fernandez-Puente P, Calamia V, Fernandez-Lopez C, Oreiro N, Ruiz-Romero C, Blanco FJ: **Differential protein profiling of synovial fluid from rheumatoid arthritis and osteoarthritis patients using LC-MALDI TOF/TOF**. *J Proteomics* 2012, **75**:2869-2878.

57. Brophy RH, Rai MF, Zhang Z, Torgomyan A, Sandell LJ: **Molecular analysis of age and sex-related gene expression in meniscal tears with and without a concomitant anterior cruciate ligament tear**. *J Bone Joint Surg Am* 2012, **94**:385-393.

58. Rai MF, Patra D, Sandell LJ, Brophy RH: **Transcriptome analysis of injured human meniscus reveals a distinct phenotype of meniscus degeneration with aging**. *Arthritis Rheum* 2013, **65**:2090-2101.

59. Hashimoto K, Otero M, Imagawa K, de Andres MC, Coico JM, Roach HI, Oreffo RO, Marcu KB, Goldring MB: **Regulated transcription of human matrix metalloproteinase 13 (MMP13) and interleukin-1β (IL1B) genes in chondrocytes depends on methylation of specific proximal promoter CpG sites**. *J Biol Chem* 2013, **288**:10061-10072.

60. Yang S, Kim J, Ryu JH, Oh H, Chun CH, Kim BJ, Min BH, Chun JS: **Hypoxia-inducible factor-2α is a catabolic regulator of osteoarthritic cartilage destruction**. *Nat Med* 2010, **16**:687-693.

61. Ruan MZ, Erez A, Guse K, Dawson B, Bertin T, Chen Y, Jiang MM,
•• Yustein J, Gannon F, Lee BH: **Proteoglycan 4 expression protects against the development of osteoarthritis**. *Sci Transl Med* 2013, **5**:176ra134.
This paper highlights lubricin, encoded by the PRG4 gene, as a potential chondroprotective agent that prevents the induction of catabolic and hypertrophy-related responses and protects against aging-related and post-traumatic OA development in mice.

62. Kim JH, Jeon J, Shin M, Won Y, Lee M, Kwak JS, Lee G, Rhee J,
•• Ryu JH, Chun CH *et al.*: **Regulation of the catabolic cascade in osteoarthritis by the zinc-ZIP8-MTF1 axis**. *Cell* 2014, **156**:730-743.

This report highlights a novel inflammation and hypoxia-regulated pathway, the Zinc-ZIP8-MTF1 axis, involving the Zn^{2+} transporter and a metal regulatory transcription factor, MTF1.

63. Otero M, Plumb DA, Tsuchimochi K, Dragomir CL, Hashimoto K, Peng H, Olivotto E, Bevilacqua M, Tan L, Yang Z et al.: **E74-like factor 3 (ELF3) impacts on matrix metalloproteinase 13 (MMP13) transcriptional control in articular chondrocytes under proinflammatory stress**. *J Biol Chem* 2012, **287**:3559-3572.

64. Hirata M, Kugimiya F, Fukai A, Saito T, Yano F, Ikeda T, Mabuchi A, Sapkota BR, Akune T, Nishida N et al.: **C/EBPβ and RUNX2 cooperate to degrade cartilage with MMP-13 as the target and HIF-2α as the inducer in chondrocytes**. *Hum Mol Genet* 2012, **21**:1111-1123.

65. Olivotto E, Otero M, Astolfi A, Platano D, Facchini A, Pagani S,
•• Flamigni F, Facchini A, Goldring MB, Borzi RM et al.: **IKKα/CHUK regulates extracellular matrix remodeling independent of its kinase activity to facilitate articular chondrocyte differentiation**. *PLoS One* 2013, **8**:e73024.
This paper reports a novel mechanism by which IKKα regulates MMP-13 activity through upregulating gene expression of its activator, MMP-10.

66. Frisenda S, Perricone C, Valesini G: **Cartilage as a target of autoimmunity: a thin layer**. *Autoimmun Rev* 2013, **12**:591-598.

67. Haseeb A, Haqqi TM: **Immunopathogenesis of osteoarthritis**. *Clin Immunol* 2013, **146**:185-196.

68. Berenbaum F: **Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!)**. *Osteoarthritis Cartilage* 2013, **21**:16-21.

69. Liu-Bryan R: **Synovium and the innate inflammatory network in osteoarthritis progression**. *Curr Rheumatol Rep* 2013, **15**:323.

70. Nair A, Kanda V, Bush-Joseph C, Verma N, Chubinskaya S, Mikecz K, Glant TT, Malfait AM, Crow MK, Spear GT et al.: **Synovial fluid from patients with early osteoarthritis modulates fibroblast-like synoviocyte responses to toll-like receptor 4 and toll-like receptor 2 ligands via soluble CD14**. *Arthritis Rheum* 2012, **64**:2268-2277.

71. Gomez R, Villalvilla A, Largo R, Gualillo O, Herrero-Beaumont G: **TLR4 signalling in osteoarthritis-finding targets for candidate DMOADs**. *Nat Rev Rheumatol* 2014, **11**:159-170.

72. Nasi S, Ea HK, Chobaz V, van Lent P, Liote F, So A, Busso N: **Dispensable role of myeloid differentiation primary response gene 88 (MyD88) and MyD88-dependent toll-like receptors (TLRs) in a murine model of osteoarthritis**. *Joint Bone Spine* 2014, **81**:320-324.

73. Fernandez-Puente P, Mateos J, Fernandez-Costa C, Oreiro N, Fernandez-Lopez C, Ruiz-Romero C, Blanco FJ: **Identification of a panel of novel serum osteoarthritis biomarkers**. *J Proteome Res* 2011, **10**:5095-5101.

74. Wanner J, Subbaiah R, Skomorovska-Prokvolit Y, Shishani Y, Boilard E, Mohan S, Gillespie R, Miyagi M, Gobezie R: **Proteomic profiling and functional characterization of early and late shoulder osteoarthritis**. *Arthritis Res Ther* 2013, **15**:R180.

75. Melin Furst C, Morgelin M, Vadstrup K, Heinegard D, Aspberg A, Blom AM: **The C-type lectin of the aggrecan G3 domain activates complement**. *PLoS One* 2013, **8**:e61407.

76. Happonen KE, Saxne T, Geborek P, Andersson M, Bengtsson AA, Hesselstrand R, Heinegard D, Blom AM: **Serum COMP-C3b complexes in rheumatic diseases and relation to anti-TNF-α treatment**. *Arthritis Res Ther* 2012, **14**:R15.

77. Wang Q, Rozelle AL, Lepus CM, Scanzello CR, Song JJ, Larsen DM, Crish JF, Bebek G, Ritter SY, Lindstrom TM et al.: **Identification of a central role for complement in osteoarthritis**. *Nat Med* 2011, **17**:1674-1679.

78. Lepus CM, Song JJ, Wang Q, Wagner CA, Lindstrom TM, Chu CR, Sokolove J, Leung LL, Robinson WH: **Brief report: carboxypeptidase B serves as a protective mediator in osteoarthritis**. *Arthritis Rheumatol* 2014, **66**:101-106.

79. Sridhar S, Botbol Y, Macian F, Cuervo AM: **Autophagy and disease: always two sides to a problem**. *J Pathol* 2012, **226**:255-273.

80. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G: **The hallmarks of aging**. *Cell* 2013, **153**:1194-1217.

81. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA et al.: **Guidelines for the use and interpretation of assays for monitoring autophagy**. *Autophagy* 2012, **8**:445-544.

82. Lotz M, Carames B: **Autophagy: a new therapeutic target in cartilage injury and osteoarthritis**. *J Am Acad Orthop Surg* 2012, **20**:261-262.

83. Lotz MK, Carames B: **Autophagy and cartilage homeostasis mechanisms in joint health, aging and OA**. *Nat Rev Rheumatol* 2011, **7**:579-587.

84. Sasaki H, Takayama K, Matsushita T, Ishida K, Kubo S, Matsumoto T, Fujita N, Oka S, Kurosaka M, Kuroda R: **Autophagy modulates osteoarthritis-related gene expression in human chondrocytes**. *Arthritis Rheum* 2012, **64**:1920-1928.

85. Carames B, Hasegawa A, Taniguchi N, Miyaki S, Blanco FJ, Lotz M: **Autophagy activation by rapamycin reduces severity of experimental osteoarthritis**. *Ann Rheum Dis* 2012, **71**:575-581.

86. Carames B, Taniguchi N, Seino D, Blanco FJ, D'Lima D, Lotz M: **Mechanical injury suppresses autophagy regulators and pharmacologic activation of autophagy results in chondroprotection**. *Arthritis Rheum* 2012, **64**:1182-1192.

87. Vasheghani F, Monemdjou R, Fahmi H, Zhang Y, Perez G, Blati M, St-Arnaud R, Pelletier JP, Beier F, Martel-Pelletier J et al.: **Adult cartilage-specific peroxisome proliferator-activated receptor γ knockout mice exhibit the spontaneous osteoarthritis phenotype**. *Am J Pathol* 2013, **182**:1099-1106.

88. Patra D, DeLassus E, Liang G, Sandell LJ: **Cartilage-specific ablation of site-1 protease in mice results in the endoplasmic reticulum entrapment of type IIb procollagen and down-regulation of cholesterol and lipid homeostasis**. *PLoS One* 2014, **9**:e105674.

89. Liang G, Lian C, Huang D, Gao W, Liang A, Peng Y, Ye W, Wu Z, Su P, Huang D: **Endoplasmic reticulum stress-unfolding protein response-apoptosis cascade causes chondrodysplasia in a col2a1 p.Gly1170Ser mutated mouse model**. *PLoS One* 2014, **9**:e86894.

90. Pirog KA, Irman A, Young S, Halai P, Bell PA, Boot-Handford RP, Briggs MD: **Abnormal chondrocyte apoptosis in the cartilage growth plate is influenced by genetic background and deletion of CHOP in a targeted mouse model of pseudoachondroplasia**. *PLoS One* 2014, **9**:e85145.

91. Husa M, Petursson F, Lotz M, Terkeltaub R, Liu-Bryan R: **C/EBP homologous protein drives pro-catabolic responses in chondrocytes**. *Arthritis Res Ther* 2013, **15**:R218.

92. Guo FJ, Xiong Z, Lu X, Ye M, Han X, Jiang R: **ATF6 upregulates XBP1S and inhibits ER stress-mediated apoptosis in osteoarthritis cartilage**. *Cell Signal* 2014, **26**:332-342.

93. Beier F, Loeser RF: **Biology and pathology of Rho GTPase, PI-3 kinase-Akt, and MAP kinase signaling pathways in chondrocytes**. *J Cell Biochem* 2010, **110**:573-580.

94. Ikegami D, Akiyama H, Suzuki A, Nakamura T, Nakano T, Yoshikawa H, Tsumaki N: **Sox9 sustains chondrocyte survival and hypertrophy in part through Pik3ca-Akt pathways**. *Development* 2011, **138**:1507-1519.

95. Kostopoulou F, Gkretsi V, Malizos KN, Iliopoulos D, Oikonomou P, Poultsides L, Tsezou A: **Central role of SREBP-2 in the pathogenesis of osteoarthritis**. *PLoS One* 2012, **7**:e35753.

96. Iwasa K, Hayashi S, Fujishiro T, Kanzaki N, Hashimoto S, Sakata S, Chinzei N, Nishiyama T, Kuroda R, Kurosaka M: **PTEN regulates matrix synthesis in adult human chondrocytes under oxidative stress**. *J Orthop Res* 2014, **32**:231-237.

97. Uehara Y, Hirose J, Yamabe S, Okamoto N, Okada T, Oyadomari S, Mizuta H: **Endoplasmic reticulum stress-induced apoptosis contributes to articular cartilage degeneration via**

C/EBP homologous protein. *Osteoarthritis Cartilage* 2014, **22**:1007-1017.

98. Zhang Y, Vasheghani F, Li YH, Blati M, Simeone K, Fahmi H, Lussier B, Roughley P, Lagares D, Pelletier JP *et al.*: **Cartilage-specific deletion of mTOR upregulates autophagy and protects mice from osteoarthritis**. *Ann Rheum Dis* 2014 http://dx.doi.org/10.1136/annrheumdis-2013-204599. [Epub ahead of print].

99. Carames B, Kiosses WB, Akasaki Y, Brinson DC, Eap W, Koziol J, Lotz MK: **Glucosamine activates autophagy in vitro and in vivo**. *Arthritis Rheum* 2013, **65**:1843-1852.

100. Blanco FJ, Rego I, Ruiz-Romero C: **The role of mitochondria in osteoarthritis**. *Nat Rev Rheumatol* 2011, **7**:161-169.

101. Rego-Perez I, Fernandez-Moreno M, Soto-Hermida A, Fenandez-Lopez C, Oreiro N, Blanco FJ: **Mitochondrial genetics and osteoarthritis**. *Front Biosci (Schol Ed)* 2013, **5**:360-368.

102. Gavriilidis C, Miwa S, von Zglinicki T, Taylor RW, Young DA: **Mitochondrial dysfunction in osteoarthritis is associated with down-regulation of superoxide dismutase 2**. *Arthritis Rheum* 2013, **65**:378-387.

103. Vaamonde-Garcia C, Riveiro-Naveira RR, Valcarcel-Ares MN, Hermida-Carballo L, Blanco FJ, Lopez-Armada MJ: **Mitochondrial dysfunction increases inflammatory responsiveness to cytokines in normal human chondrocytes**. *Arthritis Rheum* 2012, **64**:2927-2936.

104. de Andres MC, Maneiro E, Martin MA, Arenas J, Blanco FJ: **Nitric oxide compounds have different effects profiles on human articular chondrocyte metabolism**. *Arthritis Res Ther* 2013, **15**:R115.

105. Mihaylova MM, Shaw RJ: **The AMPK signalling pathway coordinates cell growth, autophagy and metabolism**. *Nat Cell Biol* 2011, **13**:1016-1023.

106. Salminen A, Kaarniranta K: **AMP-activated protein kinase (AMPK) controls the aging process via an integrated signaling network**. *Ageing Res Rev* 2012, **11**:230-241.

107. Terkeltaub R, Yang B, Lotz M, Liu-Bryan R: **Chondrocyte AMP-activated protein kinase activity suppresses matrix degradation responses to proinflammatory cytokines interleukin-1β and tumor necrosis factor α**. *Arthritis Rheum* 2011, **63**:1928-1937.

108. Moon MH, Jeong JK, Lee YJ, Seol JW, Jackson CJ, Park SY: **SIRT1, a class III histone deacetylase, regulates TNF-α-induced inflammation in human chondrocytes**. *Osteoarthritis Cartilage* 2013, **21**:470-480.

109. Matsushita T, Sasaki H, Takayama K, Ishida K, Matsumoto T, Kubo S, Matsuzaki T, Nishida K, Kurosaka M, Kuroda R: **The overexpression of SIRT1 inhibited osteoarthritic gene expression changes induced by interleukin-1β in human chondrocytes**. *J Orthop Res* 2013, **31**:531-537.

110. Gabay O, Oppenhiemer H, Meir H, Zaal K, Sanchez C, Dvir-Ginzberg M: **Increased apoptotic chondrocytes in articular cartilage from adult heterozygous SirT1 mice**. *Ann Rheum Dis* 2012, **71**:613-616.

111. Dvir-Ginzberg M, Steinmeyer J: **Towards elucidating the role of SirT1 in osteoarthritis**. *Front Biosci (Landmark Ed)* 2013, **18**:343-355.

112. Gabay O, Sanchez C, Dvir-Ginzberg M, Gagarina V, Zaal KJ, Song Y, He XH, McBurney MW: **Sirtuin 1 enzymatic activity is required for cartilage homeostasis in vivo in a mouse model**. *Arthritis Rheum* 2013, **65**:159-166.

113. Petursson F, Husa M, June R, Lotz M, Terkeltaub R, Liu-Bryan R: **Linked decreases in liver kinase B1 and AMP-activated protein kinase activity modulate matrix catabolic responses to biomechanical injury in chondrocytes**. *Arthritis Res Ther* 2013, **15**:R77.

114. Matsuzaki T, Matsushita T, Takayama K, Matsumoto T, Nishida K, Kuroda R, Kurosaka M: **Disruption of Sirt1 in chondrocytes causes accelerated progression of osteoarthritis under**

mechanical stress and during ageing in mice. *Ann Rheum Dis* 2014, **73**:1397-1404.

115. Botter SM, van Osch GJ, Clockaerts S, Waarsing JH, Weinans H, van Leeuwen JP: **Osteoarthritis induction leads to early and temporal subchondral plate porosity in the tibial plateau of mice: an in vivo microfocal computed tomography study**. *Arthritis Rheum* 2011, **63**:2690-2699.

116. Gu XI, Palacio-Mancheno PE, Leong DJ, Borisov YA, Williams E, Maldonado N, Laudier D, Majeska RJ, Schaffler MB, Sun HB *et al.*: **High resolution micro arthrography of hard and soft tissues in a murine model**. *Osteoarthritis Cartilage* 2012, **20**:1011-1019.

117. Zhen G, Wen C, Jia X, Li Y, Crane JL, Mears SC, Askin FB, Frassica FJ, Chang W, Yao J *et al.*: **Inhibition of TGF-[β] signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis**. *Nat Med* 2013, **19**:704-712.

118. Saito M, Sasho T, Yamaguchi S, Ikegawa N, Akagi R, Muramatsu Y, Mukoyama S, Ochiai N, Nakamura J, Nakagawa K *et al.*: **Angiogenic activity of subchondral bone during the progression of osteoarthritis in a rabbit anterior cruciate ligament transection model**. *Osteoarthritis Cartilage* 2012, **20**:1574-1582.

119. Pan J, Wang B, Li W, Zhou X, Scherr T, Yang Y, Price C, Wang L: **Elevated cross-talk between subchondral bone and cartilage in osteoarthritic joints**. *Bone* 2012, **51**:212-217.

120. Burr DB, Gallant MA: **Bone remodelling in osteoarthritis**. *Nat Rev Rheumatol* 2012, **8**:665-673.

121. Suri S, Walsh DA: **Osteochondral alterations in osteoarthritis**. *Bone* 2012, **51**:204-211.

122. Stoppiello LA, Mapp PI, Wilson D, Hill R, Scammell BE, Walsh DA: **Structural associations of symptomatic knee osteoarthritis**. *Arthritis Rheumatol* 2014, **66**:3018-3027.

123. Lambert C, Dubuc JE, Montell E, Verges J, Munaut C, Noel A, Henrotin Y: **Gene expression pattern of cells from inflamed and normal areas of osteoarthritis synovial membrane**. *Arthritis Rheumatol* 2014, **66**:960-968.

124. Nagai T, Sato M, Kobayashi M, Yokoyama M, Tani Y, Mochida J: **Bevacizumab, an anti-vascular endothelial growth factor antibody, inhibits osteoarthritis**. *Arthritis Res Ther* 2014, **16**:427.

125. van der Kraan PM: **Age-related alterations in TGF β signaling as a causal factor of cartilage degeneration in osteoarthritis**. *Biomed Mater Eng* 2014, **24**:75-80.

126. Blaney Davidson EN, van Caam AP, Vitters EL, Bennink MB, Thijssen E, van den Berg WB, Koenders MI, van Lent PL, van de Loo FA, van der Kraan PM: **TGF-β is a potent inducer of Nerve Growth Factor in articular cartilage via the ALK5-Smad2/3 pathway. Potential role in OA related pain?** *Osteoarthritis Cartilage* 2014, **23**:478-486.

127. Bush JR, Beier F: **TGF-β and osteoarthritis — the good and the bad**. *Nat Med* 2013, **19**:667-669.

128. Vincent TL: **Explaining the fibroblast growth factor paradox in osteoarthritis: lessons from conditional knockout mice**. *Arthritis Rheum* 2012, **64**:3835-3838.

129. Yan D, Chen D, Cool SM, van Wijnen AJ, Mikecz K, Murphy G, Im HJ: **Fibroblast growth factor receptor 1 is principally responsible for fibroblast growth factor 2-induced catabolic activities in human articular chondrocytes**. *Arthritis Res Ther* 2011, **13**:R130.

130. Barr L, Getgood A, Guehring H, Rushton N, Henson FM: **The effect of recombinant human fibroblast growth factor-18 on articular cartilage following single impact load**. *J Orthop Res* 2014, **32**:923-927.

131. Mori Y, Saito T, Chang SH, Kobayashi H, Ladel CH, Guehring H, Chung UI, Kawaguchi H: **Identification of fibroblast growth factor-18 as a molecule to protect adult articular cartilage by gene expression profiling**. *J Biol Chem* 2014, **289**:10192-10200.

132. Ellman MB, Yan D, Ahmadinia K, Chen D, An HS, Im HJ: **Fibroblast growth factor control of cartilage homeostasis**. *J Cell Biochem* 2013, **114**:735-742.

133. Lohmander LS, Hellot S, Dreher D, Krantz EF, Kruger DS, Guermazi A, Eckstein F: **Intraarticular sprifermin (recombinant human fibroblast growth factor 18) in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial**. *Arthritis Rheumatol* 2014, **66**:1820-1831.

134. Lories RJ, Corr M, Lane NE: **To Wnt or not to Wnt: the bone and joint health dilemma**. *Nat Rev Rheumatol* 2013, **9**:328-339.

135. Baron R, Kneissel M: **WNT signaling in bone homeostasis and disease: from human mutations to treatments**. *Nat Med* 2013, **19**:179-192.

136. Leijten JC, Emons J, Sticht C, van Gool S, Decker E, Uitterlinden A, Rappold G, Hofman A, Rivadeneira F, Scherjon S *et al.*: **Gremlin 1, frizzled-related protein, and Dkk-1 are key regulators of human articular cartilage homeostasis**. *Arthritis Rheum* 2012, **64**:3302-3312.

137. van den Bosch MH, Blom AB, van Lent PL, van Beuningen HM,
• Blaney Davidson EN, van der Kraan PM, van den Berg WB: **Canonical Wnt signaling skews TGF-β signaling in chondrocytes towards signaling via ALK1 and Smad 1/5/8**. *Cell Signal* 2014, **26**:951-958.
Demonstrates cross talk between Wnt signaling and TGF-b via disturbing the balance between the homestatic ALK5 receptor and ALK1.

138. Oh H, Chun CH, Chun JS: **Dkk-1 expression in chondrocytes inhibits experimental osteoarthritic cartilage destruction in mice**. *Arthritis Rheum* 2012, **64**:2568-2578.

139. Baker-Lepain JC, Lynch JA, Parimi N, McCulloch CE, Nevitt MC, Corr M, Lane NE: **Variant alleles of the Wnt antagonist FRZB are determinants of hip shape and modify the relationship between hip shape and osteoarthritis**. *Arthritis Rheum* 2012, **64**:1457-1465.

140. Bougault C, Priam S, Houard X, Pigenet A, Sudre L, Lories RJ, Jacques C, Berenbaum F: **Protective role of frizzled-related protein B on matrix metalloproteinase induction in mouse chondrocytes**. *Arthritis Res Ther* 2014, **16**:R137.

141. Funck-Brentano T, Bouaziz W, Marty C, Geoffroy V, Hay E, Cohen-Solal M: **Dkk1-mediated inhibition of Wnt signaling in bone ameliorates osteoarthritis**. *Arthritis Rheumatol* 2014, **66**:3028-3039.

142. Mabey T, Honsawek S, Tanavalee A, Wilairatana V, Yuktanandana P, Saetan N, Zhan D: **Plasma and synovial fluid sclerostin are inversely associated with radiographic severity of knee osteoarthritis**. *Clin Biochem* 2014, **47**:547-551.

143. Chan BY, Fuller ES, Russell AK, Smith SM, Smith MM, Jackson MT, Cake MA, Read RA, Bateman JF, Sambrook PN *et al.*: **Increased chondrocyte sclerostin may protect against cartilage degradation in osteoarthritis**. *Osteoarthritis Cartilage* 2011, **19**:874-885.

144. Lewiecki EM: **Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases**. *Ther Adv Musculoskelet Dis* 2014, **6**:48-57.

145. Roudier M, Li X, Niu QT, Pacheco E, Pretorius JK, Graham K, Yoon BR, Gong J, Warmington K, Ke HZ *et al.*: **Sclerostin is expressed in articular cartilage but loss or inhibition does not affect cartilage remodeling during aging or following mechanical injury**. *Arthritis Rheum* 2013, **65**:721-731.

146. Gelse K, Ekici AB, Cipa F, Swoboda B, Carl HD, Olk A, Hennig FF, Klinger P: **Molecular differentiation between osteophytic and articular cartilage — clues for a transient and permanent chondrocyte phenotype**. *Osteoarthritis Cartilage* 2012, **20**:162-171.

147. Nguyen J, Tang SY, Nguyen D, Alliston T: **Load regulates bone formation and Sclerostin expression through a TGFβ-dependent mechanism**. *PLoS One* 2013, **8**:e53813.

148. Minashima T, Zhang Y, Lee Y, Kirsch T: **Lithium protects against cartilage degradation in osteoarthritis**. *Arthritis Rheumatol* 2014, **66**:1228-1236.

149. Jiang Y, Tuan RS: **Origin and function of cartilage stem/
•• progenitor cells in osteoarthritis**. *Nat Rev Rheumatol* 2015, **11**:206-212.
Reviews current research on progenitor cells for repairing cartilage and the potential for developing stem cell-based therapy.

150. Miller RE, Tran PB, Das R, Ghoreishi-Haack N, Ren D, Miller RJ,
•• Malfait AM: **CCR2 chemokine receptor signaling mediates pain in experimental osteoarthritis**. *Proc Natl Acad Sci U S A* 2012, **109**:20602-20607.
Indicates that targeting the CCR2 chemokine receptor could address both pain and structure modification.

151. Bullock CM, Wookey P, Bennett A, Mobasheri A, Dickerson I, Kelly S: **Peripheral calcitonin gene-related peptide receptor activation and mechanical sensitization of the joint in rat models of osteoarthritis pain**. *Arthritis Rheumatol* 2014, **66**:2188-2200.

152. O'Conor CJ, Leddy HA, Benefield HC, Liedtke WB, Guilak F:
•• **TRPV4-mediated mechanotransduction regulates the metabolic response of chondrocytes to dynamic loading**. *Proc Natl Acad Sci U S A* 2014, **111**:1316-1321.
Suggests potential to address pain and structure modification by targeting transient receptor potential vanilloid ion channels.

153. Csermely P, Korcsmaros T, Kiss HJ, London G, Nussinov R: **Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review**. *Pharmacol Ther* 2013, **138**:333-408.

154. Zhang L, Yang M, Marks P, White LM, Hurtig M, Mi QS, Divine G,
• Gibson G: **Serum non-coding RNAs as biomarkers for osteoarthritis progression after ACL injury**. *Osteoarthritis Cartilage* 2012, **20**:1631-1637.
The first report of a circulating non-coding RNA that may serve as an OA biomarker.

155. Beyer C, Zampetaki A, Lin NY, Kleyer A, Perricone C, Iagnocco A, Distler A, Langley SR, Gelse K, Sesselmann S *et al.*: **Signature of circulating microRNAs in osteoarthritis**. *Ann Rheum Dis* 2015, **74**:e18.

156. Goldring MB, Marcu KB: **Epigenomic and microRNA-mediated regulation in cartilage development, homeostasis, and osteoarthritis**. *Trends Mol Med* 2012, **18**:109-118.

157. Zhang X, Siclari VA, Lan S, Zhu J, Koyama E, Dupuis HL, Enomoto-Iwamoto M, Beier F, Qin L: **The critical role of the epidermal growth factor receptor in endochondral ossification**. *J Bone Miner Res* 2011, **26**:2622-2633.

158. Usmani SE, Pest MA, Kim G, Ohora SN, Qin L, Beier F: **Transforming growth factor α controls the transition from hypertrophic cartilage to bone during endochondral bone growth**. *Bone* 2012, **51**:131-141.

159. Hall KC, Hill D, Otero M, Plumb DA, Froemel D, Dragomir CL, Maretzky T, Boskey A, Crawford HC, Selleri L *et al.*: **ADAM17 controls endochondral ossification by regulating terminal differentiation of chondrocytes**. *Mol Cell Biol* 2013, **33**:3077-3090.

160. Hayami T, Zhuo Y, Wesolowski GA, Pickarski M, Duong le T: **Inhibition of cathepsin K reduces cartilage degeneration in the anterior cruciate ligament transection rabbit and murine models of osteoarthritis**. *Bone* 2012, **50**:1250-1259.

161. Miller RE, Lu Y, Tortorella MD, Malfait AM: **Genetically engineered mouse models reveal the importance of proteases as osteoarthritis drug targets**. *Curr Rheumatol Rep* 2013, **15**:350.

162. Leong DJ, Choudhury M, Hanstein R, Hirsh DM, Kim S, Majeska RJ, Schaffler MB, Hardin JA, Spray DC, Goldring MB *et al.*: **Green tea polyphenol treatment is chondroprotective, anti-inflammatory and palliative in a mouse post-traumatic osteoarthritis model**. *Arthritis Res Ther* 2014, **16**:508.

163. Bowles RD, Mata BA, Bell RD, Mwangi TK, Huebner JL, Kraus VB, Setton LA: **In vivo luminescence imaging of NF-κB activity and serum cytokine levels predict pain sensitivities in a rodent model of osteoarthritis**. *Arthritis Rheumatol* 2014, **66**:637-646.

164. Hu W, Zhang W, Li F, Guo F, Chen A: **Bortezomib prevents the expression of MMP-13 and the degradation of collagen type 2 in human chondrocytes**. *Biochem Biophys Res Commun* 2014, **452**:526-530.

165. van Beuningen HM, de Vries-van Melle ML, Vitters EL, Schreurs W, van den Berg WB, van Osch GJ, van der Kraan PM: **Inhibition of TAK1 and/or JAK can rescue impaired chondrogenic**

differentiation of human mesenchymal stem cells in osteoarthritis-like conditions. *Tissue Eng Part A* 2014, **20**:2243-2252.

166. de Andres MC, Imagawa K, Hashimoto K, Gonzalez A, Goldring MB, Roach HI, Oreffo RO: **Suppressors of cytokine signalling (SOCS) are reduced in osteoarthritis**. *Biochem Biophys Res Commun* 2011, **407**:54-59.

167. van de Loo FA, Veenbergen S, van den Brand B, Bennink MB, Blaney-Davidson E, Arntz OJ, van Beuningen HM, van der Kraan PM, van den Berg WB: **Enhanced suppressor of cytokine signaling 3 in arthritic cartilage dysregulates human chondrocyte function**. *Arthritis Rheum* 2012, **64**:3313-3323.

168. Wolff KJ, Ramakrishnan PS, Brouillette MJ, Journot BJ, McKinley TO, Buckwalter JA, Martin JA: **Mechanical stress and ATP synthesis are coupled by mitochondrial oxidants in articular cartilage**. *J Orthop Res* 2013, **31**:191-196.

169. Lin AC, Seeto BL, Bartoszko JM, Khoury MA, Whetstone H, Ho L, Hsu C, Ali AS, Alman BA: **Modulating hedgehog signaling can attenuate the severity of osteoarthritis**. *Nat Med* 2009, **15**:1421-1425.

170. Ruiz-Heiland G, Horn A, Zerr P, Hofstetter W, Baum W, Stock M, Distler JH, Nimmerjahn F, Schett G, Zwerina J: **Blockade of the hedgehog pathway inhibits osteophyte formation in arthritis**. *Ann Rheum Dis* 2012, **71**:400-407.

171. Mirando AJ, Liu Z, Moore T, Lang A, Kohn A, Osinski AM, O'Keefe RJ, Mooney RA, Zuscik MJ, Hilton MJ: **RBP-Jκ-dependent Notch signaling is required for murine articular cartilage and joint maintenance**. *Arthritis Rheum* 2013, **65**:2623-2633.

172. Hosaka Y, Saito T, Sugita S, Hikata T, Kobayashi H, Fukai A, Taniguchi Y, Hirata M, Akiyama H, Chung UI *et al.*: **Notch signaling in chondrocytes modulates endochondral ossification and osteoarthritis development**. *Proc Natl Acad Sci U S A* 2013, **110**:1875-1880.

173. Zhao R, Wang A, Hall KC, Otero M, Weskamp G, Zhao B, Hill D, Goldring MB, Glomski K, Blobel CP: **Lack of ADAM10 in endothelial cells affects osteoclasts at the chondro-osseous junction**. *J Orthop Res* 2014, **32**:224-230.

174. Ji RR, Xu ZZ, Gao YJ: **Emerging targets in neuroinflammation-driven chronic pain**. *Nat Rev Drug Discov* 2014, **13**:533-548.

175. Mediero A, Wilder T, Perez-Aso M, Cronstein BN: **Direct or indirect stimulation of adenosine A2A receptors enhances bone regeneration as well as bone morphogenetic protein-2**. *FASEB J* 2015, **29**:1577-1590.

176. Rosenthal AK, Gohr CM, Mitton-Fitzgerald E, Lutz MK, Dubyak GR, Ryan LM: **The progressive ankylosis gene product ANK regulates extracellular ATP levels in primary articular chondrocytes**. *Arthritis Res Ther* 2013, **15**:R154.

177. Cohen S, Barer F, Bar-Yehuda S, A.P IJ, Jacobson KA, Fishman P: **A(3) adenosine receptor allosteric modulator induces an anti-inflammatory effect: in vivo studies and molecular mechanism of action**. *Mediators Inflamm* 2014, **2014**:708746.

178. Bonet ML, Granados N, Palou A: **Molecular players at the intersection of obesity and osteoarthritis**. *Curr Drug Targets* 2011, **12**:2103-2128.

179. Chen YJ, Sheu ML, Tsai KS, Yang RS, Liu SH: **Advanced glycation end products induce peroxisome proliferator-activated receptor γ down-regulation-related inflammatory signals in human chondrocytes via Toll-like receptor-4 and receptor for advanced glycation end products**. *PLoS One* 2013, **8**:e66611.

180. Sherwood J, Bertrand J, Nalesso G, Poulet B, Pitsillides A,
• Brandolini L, Karystinou A, De Bari C, Luyten FP, Pitzalis C *et al.*: **A homeostatic function of CXCR2 signalling in articular cartilage**. *Ann Rheum Dis* 2014 http://dx.doi.org/10.1136/annrheumdis-2014-205546. Aug 18. pii:annrheumdis-2014-205546. [Epub ahead of print].

Reports the possible role of a chemokine receptor in cartilage homeostasis and its potential for developing chondroprotective agents.

181. Yano F, Hojo H, Ohba S, Fukai A, Hosaka Y, Ikeda T, Saito T, Hirata M, Chikuda H, Takato T *et al.*: **A novel disease-modifying osteoarthritis drug candidate targeting Runx1**. *Ann Rheum Dis* 2013, **72**:748-753.

182. Johnson K, Zhu S, Tremblay MS, Payette JN, Wang J, Bouchez LC, Meeusen S, Althage A, Cho CY, Wu X *et al.*: **A stem cell-based approach to cartilage repair**. *Science* 2012, **336**:717-721.

183. Kang ML, Ko JY, Kim JE, Im GI: **Intra-articular delivery of kartogenin-conjugated chitosan nano/microparticles for cartilage regeneration**. *Biomaterials* 2014, **35**:9984-9994.

184. Sampson ER, Hilton MJ, Tian Y, Chen D, Schwarz EM, Mooney RA, Bukata SV, O'Keefe RJ, Awad H, Puzas JE *et al.*: **Teriparatide as a chondroregenerative therapy for injury-induced osteoarthritis**. *Sci Transl Med* 2011, **3**:101ra193.

185. Pest MA, Russell BA, Zhang YW, Jeong JW, Beier F: **Disturbed cartilage and joint homeostasis resulting from a loss of mitogen-inducible gene 6 in a mouse model of joint dysfunction**. *Arthritis Rheumatol* 2014, **66**:2816-2827.

186. Bertrand J, Nitschke Y, Fuerst M, Hermann S, Schafers M, Sherwood J, Nalesso G, Ruether W, Rutsch F, Dell'Accio F *et al.*: **Decreased levels of nucleotide pyrophosphatase phosphodiesterase 1 are associated with cartilage calcification in osteoarthritis and trigger osteoarthritic changes in mice**. *Ann Rheum Dis* 2012, **71**:1249-1253.

187. Hunter DJ, Pike MC, Jonas BL, Kissin E, Krop J, McAlindon T: **Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritis**. *BMC Musculoskelet Disord* 2010, **11**:232.

188. Loffredo FS, Pancoast JR, Cai L, Vannelli T, Dong JZ, Lee RT, Patwari P: **Targeted delivery to cartilage is critical for in vivo efficacy of insulin-like growth factor 1 in a rat model of osteoarthritis**. *Arthritis Rheumatol* 2014, **66**:1247-1255.

189. Mero A, Campisi M, Favero M, Barbera C, Secchieri C, Dayer JM, Goldring MB, Goldring SR, Pasut G: **A hyaluronic acid-salmon calcitonin conjugate for the local treatment of osteoarthritis: chondro-protective effect in a rabbit model of early OA**. *J Control Release* 2014, **187**:30-38.

190. Esenyel M, Icagasioglu A, Esenyel CZ: **Effects of calcitonin on knee osteoarthritis and quality of life**. *Rheumatol Int* 2013, **33**:423-427.

191. Karsdal MA, Byrjalsen I, Alexandersen P, Bihlet A, Andersen JR, Riis BJ, Bay-Jensen AC, Christiansen C: **Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials**. *Osteoarthritis Cartilage* 2015, **23**:532-543.

192. Greenblatt MB, Ritter SY, Wright J, Tsang K, Hu D, Glimcher LH, Aliprantis AO: **NFATc1 and NFATc2 repress spontaneous osteoarthritis**. *Proc Natl Acad Sci U S A* 2013, **110**:19914-19919.

193. Greco KV, Nalesso G, Kaneva MK, Sherwood J, Iqbal AJ, Moradi-Bidhendi N, Dell'Accio F, Perretti M: **Analyses on the mechanisms that underlie the chondroprotective properties of calcitonin**. *Biochem Pharmacol* 2014, **91**:348-358.

194. Gossan N, Zeef L, Hensman J, Hughes A, Bateman JF, Rowley L,
• Little CB, Piggins HD, Rattray M, Boot-Handford RP *et al.*: **The circadian clock in murine chondrocytes regulates genes controlling key aspects of cartilage homeostasis**. *Arthritis Rheum* 2013, **65**:2334-2345.

Suggests the potential role of the circadian clock in cartilage in modulating responses to drug therapy.

195. Solt LA, Wang Y, Banerjee S, Hughes T, Kojetin DJ, Lundasen T, Shin Y, Liu J, Cameron MD, Noel R *et al.*: **Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists**. *Nature* 2012, **485**:62-68.